🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

286 results for “Hoffmann-La Roche” Clear

  1. A study investigating the effect of different approved medications on how the body processes the study compound RO7795081. RO7795081 is a new compound that may potentially be used in the treatment of type 2 diabetes and weight control.

    Hoffmann-La Roche

    Type 2 Diabetes and obesity

    phase 1 other active

    1 trial

  2. A study investigating the safety of RO7795081 and the effect of RO7795081 on how the body processes different approved medications. RO7795081 is a new compound that may potentially be used in the treatment of type 2 diabetes and weight control

    Hoffmann-La Roche

    Obesity or Overweight

    phase 1 other active

    1 trial

  3. A study investigating the safety, absorption, and elimination of RO7795068, a new compound that may potentially be used in the treatment of obesity

    Hoffmann-La Roche

    Healthy volunteers

    phase 1 other active

    1 trial

  4. A study investigating the safety, absorption, and elimination of RO7795068, a new compound that may potentially be used in the treatment of obesity

    Hoffmann-La Roche

    Not Applicable

    phase 1 other active

    1 trial

  5. A study investigating the safety, absorption, and elimination of RO7795081, a new compound that may potentially be used in the treatment of type 2 diabetes and weight control

    Hoffmann-La Roche

    Not Applicable

    phase 1 other active

    1 trial

  6. A study investigating the safety, absorption, and elimination of radioactively labeled RO7269162, a new compound that may potentially be used in the treatment of Alzheimer’s disease.

    Hoffmann-La Roche

    Healthy males volunteers

    phase 1 other active

    1 trial

  7. A study to evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and preliminary Anti-Tumor activity of RO7616789 in participants with Advanced Small Cell Lung Cancer and other Neuroendocrine Carcinomas

    Hoffmann-La Roche

    Small Cell Lung Cancer and Neuroendocrine Carcinoma

    phase 1 other active

    1 trial

  8. A study to see how RO7763505 works and how safe it is when given to healthy people and people with stable heart disease

    Hoffmann-La Roche

    Stable Coronary Artery Disease (CAD)

    phase 1 other active

    1 trial

  9. A study to test the biological properties of RO7568282 and whether it is safe in healthy participants and participants with Parkinson’s disease.

    Hoffmann-La Roche

    Parkinson’s Disease

    phase 1 other active

    1 trial

  10. An Early-Stage Study in Multiple Clinics of how Afimkibart May Affect the Body’s Processing of Medicines that Rely on Cytochrome P450 Enzymes in Patients with Ulcerative Colitis

    Hoffmann-La Roche

    Active Ulcerative Colitis (UC)

    phase 1 other active

    1 trial

  11. An early Phase 1b Study to assess how safe and effective is the treatment with drugs, called Mosunetuzumab or Glofitamab in Combination with drugs called, CC-220 and CC-99282 in Patients with B-Cell Non-Hodgkin Lymphoma.

    Hoffmann-La Roche

    Non-Hodgkin Lymphoma

    phase 1 other active

    1 trial

  12. Atezolizumab

    Hoffmann-La Roche

    Advanced Ovarian Cancer

    phase 1 small molecule terminated

    1 trial

  13. First-in-Human Study of RO7812653

    Hoffmann-La Roche

    Early Symptomatic Alzheimer’s Disease (eAD), (Mild Cognitive Impairment due to AD, or probable AD dementia)

    phase 1 other active

    1 trial

  14. Ipatasertib

    Hoffmann-La Roche

    Breast Cancer

    phase 1 small molecule terminated

    1 trial

  15. Midazolam

    Hoffmann-La Roche

    Hepatitis B, Chronic

    phase 1 small molecule completed

    1 trial

  16. Multiple Dose Study of RO7795068 and its effect on Gastric Emptying, and on PK of Oral Contraceptives

    Hoffmann-La Roche

    Healthy Overweight or Obese

    phase 1 other active

    1 trial

  17. Onartuzumab

    Hoffmann-La Roche

    Carcinoma, Hepatocellular

    phase 1 small molecule completed

    1 trial

  18. PEG-IFN alfa-2a BA-free formulation (Test)

    Hoffmann-La Roche

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  19. Placebo - MAD

    Hoffmann-La Roche

    Healthy Volunteer

    phase 1 small molecule completed

    1 trial

  20. RO5323441

    Hoffmann-La Roche

    Carcinoma, Hepatocellular

    phase 1 small molecule completed

    1 trial

  21. RO5503781

    Hoffmann-La Roche

    Neoplasms

    phase 1 small molecule completed

    1 trial

  22. RO5503781 MBP

    Hoffmann-La Roche

    Myelogenous Leukemia, Acute

    phase 1 small molecule completed

    1 trial

  23. RO7119929

    Hoffmann-La Roche

    Carcinoma, Hepatocellular

    phase 1 small molecule completed

    1 trial

  24. RO7507062

    Hoffmann-La Roche

    Systemic Lupus Erythematosus

    phase 1 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources